Pediatric Medication Concerns

  1. guidelines for preventing medication errors in pediatrics

    risk of strangulation of infants by iv tubing and monitor leads

    measuring pediatric iron products safely

    asphyxiation possible with syringe tip caps. do not provide hypodermic syringes to parents for administering oral liquids to children

    children at risk from brightly colored pills

    accidental childhood acetaminophen overdoses illustrate our responsibility to educate parents
    tragic confusion over tylenol infants' drops and children's tylenol. the infant drops has 3 times the acetamophen concentration.

    unsafe tylenol packaging.
    new children's tylenol meltaways (acetaminophen), for kids aged 2 to 6, quickly dissolve in a child's mouth and make swallowing the medication easy. however, the available blister package exhibits confusing labeling and packaging that could accidentally double the typical dose of medication given to small children.

    aspirin and combination products containing aspirin should not be given to children under 19 years of age - risk of reye's syndrome

    phenergan tablets and suppositories contraindicated for use in pediatric patients less than 2 years of age - potential for fatal resiratory depression.
    Last edit by VickyRN on Dec 27, '06
    •  
  2. 5 Comments

  3. by   VickyRN
    strattera -

    fda notified health care professionals in february, 2005, about a new warning for strattera, a drug approved for attention deficit hyperactivity disorder (adhd) in adults and children. the labeling was updated with a bolded warning about the potential for severe liver injury following two reports (a teenager and an adult) in patients who had been treated with strattera for several months.

    on september 30th, 2005, eli lilly added warnings to strattera's label warning of the possibility that it could cause suicidal thoughts in children and adolescents:

    [font=timesnewromanps-boldmt]
    [font=timesnewromanps-boldmt]all pediatric patients being treated with strattera should be monitored closely for [font=timesnewromanps-boldmt]suicidality, clinical worsening, and unusual changes in behavior, especially during the [font=timesnewromanps-boldmt]initial few months of a course of drug therapy, or at times of dose changes. such [font=timesnewromanps-boldmt]monitoring would generally include at least weekly face-to-face contact with patients or [font=timesnewromanps-boldmt]their family members or are givers during the first 4 weeks of treatment, then every other [font=timesnewromanps-boldmt]week visits for the next 4 weeks, then at 12 weeks, and as clinically indicated beyond 12 [font=timesnewromanps-boldmt]weeks. additional contact by telephone may be appropriate between face-to-face visits....

    [font=timesnewromanps-boldmt]families and caregivers of pediatric patients being treated with strattera should be [font=timesnewromanps-boldmt]alerted about the need to monitor patients for the emergence of agitation, irritability, [font=timesnewromanps-boldmt]unusual changes in behavior, and the other symptoms described above, as well as the [font=timesnewromanps-boldmt]emergence of suicidality, and to report such symptoms immediately to healthcare [font=timesnewromanps-boldmt]providers. such monitoring should include daily observation by families and caregivers.[font=timesnewromanps-boldmt]

    http://pi.lilly.com/us/strattera-pi.pdf
    http://www.fda.gov/medwatch/safety/2...rattera_pi.pdf
  4. by   VickyRN
    In February, 2005 & September, 2006 - the FDA released this warning concerning Cymbalta:

    Suicidality in Children and Adolescents-Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Cymbalta or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Cymbalta is not approved for use in pediatric patients.
    http://www.fda.gov/medwatch/safety/2...ymbalta_PI.pdf
  5. by   VickyRN
    paxil - contraindicated pediatric patients; possible suicidal ideation adolescents

    suicidality in children and adolescents
    [font=klgofi+timesnewroman,bold,times new roman]

    [font=klgofi+timesnewroman,bold,times new roman]
    antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with major depressive disorder (mdd) and other psychiatric disorders. anyone considering the use of paxil or any other antidepressant in a child or adolescent must balance this risk with the clinical need. patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. families and caregivers should be advised of the need for close observation and communication with the prescriber. paxil is not approved for use in pediatric patients.
    http://www.fda.gov/medwatch/safety/2...20_9-27-05.pdf
  6. by   Charly retired rn
    Any info on 11 yr old male child on Respidol and 35 mg ritalin?? I know he has some anger problems but dont know his dx.
    Thanks
  7. by   tango delta
    Hi i just want to know the precautions in administration of propylthiouracil in peadiatrics.
    Thanks

close